EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide

Yujiro Nagata, Takaomi Sugi, Sohei Yamamura, Yoshihiro Sugita, Yui Mizushima, Takuo Matsukawa, Tomohisa Takaba, Kazumasa Jojima, Katsuyoshi Higashijima, Masahiro Matsumoto, Akinori Minato, Ikko Tomisaki und 2 weitere

In Vivo · 2025

DOI: 10.21873/invivo.14016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift In Vivo, 2025. Verfasst von Yujiro Nagata und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; yujiro-nagata@med.uoeh-u.ac.jp. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Prostate-Specific Antigen, Androgen Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPhenylthiohydantoinProstate-Specific AntigenAndrogen AntagonistsHumansMaleNitrilesBenzamidesAgedPrognosisMiddle AgedAged, 80 and overTreatment OutcomeNeoplasm MetastasisBiomarkers, Tumor

Stichwörter der Autor:innen

Castration-resistant prostate cancerandrogen-deprivation therapyenzalutamideinitial-to-nadir prostate-specific antigen ratio

Substanzen

enzalutamideNitrilesBenzamidesPhenylthiohydantoinProstate-Specific AntigenAndrogen AntagonistsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan; yujiro-nagata@med.uoeh-u.ac.jp.
  • Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Urology, Wakamatsu Hospital of University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Urology, Local Incorporated Administrative Agency Kurate Hospital, Kurate, Japan.

Zitieren

APA

Nagata, Y., Sugi, T., Yamamura, S., Sugita, Y., Mizushima, Y., Matsukawa, T., Takaba, T., Jojima, K., Higashijima, K., Matsumoto, M., Minato, A., Tomisaki, I., Kashiwagi, E., & Fujimoto, N. (2025). Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide. In Vivo. https://doi.org/10.21873/invivo.14016

Vancouver

Nagata Y, Sugi T, Yamamura S, Sugita Y, Mizushima Y, Matsukawa T, et al. Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide. In Vivo. 2025. doi:10.21873/invivo.14016

BibTeX
@article{Nagata2025,
  author = {Nagata, Yujiro and Sugi, Takaomi and Yamamura, Sohei and Sugita, Yoshihiro and Mizushima, Yui and Matsukawa, Takuo and Takaba, Tomohisa and Jojima, Kazumasa and Higashijima, Katsuyoshi and Matsumoto, Masahiro and Minato, Akinori and Tomisaki, Ikko and Kashiwagi, Eiji and Fujimoto, Naohiro},
  title = {Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.14016}
}
Kostenlos starten →